Arrhythmia Alliance

National Institute for Health and Clinical Excellence

Multiple Technology Appraisal

Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure (review of TA95 and TA120)

Response from: Arrhythmia Alliance

Prepared by , MBE FRCP (Edin)

Arrhythmia Alliance is delighted to have the opportunity to comment on the Appraisal Consultation Document on implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure (review of TA95 and TA120), published in January 2014.

It is clear that the proposals are indeed an improvement on current guidelines; however we are extremely concerned that should the proposed guidance be approved, then those patients with LVEF ≤ 35% and QRS< 120ms will be at high risk of sudden cardiac death.

These patients as detailed above are included for devices in the American College of Cardiology Guidelines, AHA Guidelines and HRS Guidelines, more importantly; the ESC Guidelines also include these patients.

We would question why UK patients should be denied access to the same therapy and in turn quality of life as their European counterparts.